The clinical examination room has long been considered the final frontier for artificial intelligence, a space where the unpredictable nature of human illness meets the rigid logic of computational code. For decades, the prospect of a machine diagnosing a patient was confined to science fiction or
Every year, millions of hospital admissions across the globe are complicated by the sudden and silent onset of blood clots within the deep veins of the lower limbs or the pulmonary arteries. This phenomenon, known as venous thromboembolism, remains a formidable challenge for cardiovascular medicine
The quiet frustration of reaching for a common word only to find a mental void is a burden many cancer survivors carry long after their last round of treatment. While modern medicine has achieved remarkable success in shrinking tumors and extending life, the neurological toll of these life-saving
The long-standing clinical assumption that any distant spread of pancreatic ductal adenocarcinoma necessitates an immediate transition to palliative measures is currently being challenged by a revolutionary shift toward aggressive, curative-intent interventions. Historically, a metastatic diagnosis
The landscape of Spinal Muscular Atrophy treatment has undergone a radical transformation over the past decade, yet the search for more durable and convenient therapies remains a top priority for researchers and families alike. Biogen, a pioneer in the space with the introduction of Spinraza, is
Ivan Kairatov is a seasoned biopharma expert with a distinguished background in research and development, focusing specifically on the intersection of immunology and biotechnology. With years of experience analyzing the clinical and commercial trajectories of next-generation therapies, he has
